Adia Nutrition Inc. Advances Toward United Healthcare Provider Approval for Adia Med Services, Signaling Major Growth Opportunity
Adia Nutrition Inc. (OTCQB: ADIA) is approaching a significant milestone as its medical subsidiary, Adia Med, nears final approval to become an in-network provider with United Healthcare. The anticipated approval, expected by August 1, 2025, will enable insurance coverage for Adia Med's advanced regenerative therapies including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) and Therapeutic Plasma Exchange (TPE).
The company has already initiated its first patient insurance claim through United Healthcare, signaling progress toward integration. This strategic development will expand Adia Med's market reach by making its treatments accessible to United Healthcare's extensive patient network while establishing a scalable reimbursement pathway in the regenerative medicine sector.
Adia Nutrition Inc. (OTCQB: ADIA) sta per raggiungere un traguardo importante: la sua controllata medica, Adia Med, è vicina all'approvazione finale per diventare un fornitore in rete con United Healthcare. L'approvazione prevista entro il 1° agosto 2025 permetterà la copertura assicurativa per le terapie rigenerative avanzate di Adia Med, tra cui il Trapianto Autologo di Cellule Staminali Ematopoietiche (AHSCT) e lo Scambio Terapeutico di Plasma (TPE).
L'azienda ha già avviato la sua prima richiesta di rimborso assicurativo tramite United Healthcare, segnalando progressi verso l'integrazione. Questo sviluppo strategico amplierà la portata di mercato di Adia Med, rendendo i suoi trattamenti accessibili all'ampia rete di pazienti di United Healthcare e creando un percorso di rimborso scalabile nel settore della medicina rigenerativa.
Adia Nutrition Inc. (OTCQB: ADIA) está a punto de alcanzar un hito importante, ya que su subsidiaria médica, Adia Med, se acerca a la aprobación final para convertirse en un proveedor dentro de la red de United Healthcare. Se espera que la aprobación llegue antes del 1 de agosto de 2025, lo que permitirá la cobertura de seguro para las terapias regenerativas avanzadas de Adia Med, incluyendo el Trasplante Autólogo de Células Madre Hematopoyéticas (AHSCT) y el Intercambio Terapéutico de Plasma (TPE).
La empresa ya ha iniciado su primera reclamación de seguro a través de United Healthcare, lo que indica avances hacia la integración. Este desarrollo estratégico ampliará el alcance de mercado de Adia Med, haciendo sus tratamientos accesibles a la amplia red de pacientes de United Healthcare y estableciendo un camino escalable para el reembolso en el sector de la medicina regenerativa.
Adia Nutrition Inc. (OTCQB: ADIA)는 의료 자회사인 Adia Med가 United Healthcare 네트워크 내 제공자로 최종 승인에 가까워지면서 중요한 이정표에 다가서고 있습니다. 예상 승인일은 2025년 8월 1일로, 이를 통해 Adia Med의 자가 조혈모세포 이식(AHSCT) 및 치료용 혈장 교환(TPE) 등 첨단 재생 치료에 대한 보험 적용이 가능해질 예정입니다.
회사는 이미 United Healthcare를 통한 첫 환자 보험 청구를 시작하여 통합 진행 상황을 알렸습니다. 이 전략적 발전은 Adia Med의 시장 범위를 확대하여 United Healthcare의 광범위한 환자 네트워크에 치료를 제공하고 재생 의학 분야에서 확장 가능한 보험 환급 경로를 구축할 것입니다.
Adia Nutrition Inc. (OTCQB : ADIA) s'apprête à franchir une étape importante alors que sa filiale médicale, Adia Med, approche de l'approbation finale pour devenir un fournisseur intégré au réseau de United Healthcare. L'approbation attendue, prévue pour le 1er août 2025, permettra la prise en charge par l'assurance des thérapies régénératives avancées d'Adia Med, notamment la transplantation autologue de cellules souches hématopoïétiques (AHSCT) et l'échange plasmatique thérapeutique (TPE).
L'entreprise a déjà lancé sa première demande de remboursement auprès de United Healthcare, marquant une avancée vers l'intégration. Ce développement stratégique étendra la portée d'Adia Med en rendant ses traitements accessibles au vaste réseau de patients de United Healthcare, tout en établissant une voie de remboursement évolutive dans le secteur de la médecine régénérative.
Adia Nutrition Inc. (OTCQB: ADIA) steht kurz vor einem bedeutenden Meilenstein, da seine medizinische Tochtergesellschaft Adia Med kurz vor der endgültigen Genehmigung steht, um ein Netzwerk-Anbieter bei United Healthcare zu werden. Die erwartete Genehmigung bis zum 1. August 2025 wird die Versicherungsdeckung für Adia Meds fortschrittliche regenerative Therapien, einschließlich der autologen hämatopoetischen Stammzelltransplantation (AHSCT) und des therapeutischen Plasmaaustauschs (TPE), ermöglichen.
Das Unternehmen hat bereits die erste Patientenversicherungsforderung über United Healthcare eingereicht, was auf Fortschritte bei der Integration hinweist. Diese strategische Entwicklung wird die Marktpräsenz von Adia Med erweitern, indem sie die Behandlungen einem breiten Patientennetzwerk von United Healthcare zugänglich macht und einen skalierbaren Erstattungsweg im Bereich der regenerativen Medizin etabliert.
- None.
- Final approval still pending
- Currently limited to United Healthcare network only
Winter Park, Florida--(Newsfile Corp. - July 2, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in advanced regenerative therapies, is pleased to announce that its medical subsidiary, Adia Med, is in the final stages of approval to become an in-network provider with United Healthcare, one of the largest and most influential health insurance companies in the U.S. The company anticipates final approval by August 1, 2025, which will significantly expand Adia Med's market reach by making its cutting-edge medical services eligible for reimbursement under United Healthcare policies.
United Healthcare
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/256142_adianutritionimage.jpg
This strategic milestone positions Adia Nutrition to tap into a vastly larger patient population while driving new revenue streams from insurance-backed procedures such as Autologous Hematopoietic Stem Cell Transplantation (AHSCT), Therapeutic Plasma Exchange (TPE), and stem cell therapies that may be covered under the patient's insurance.
"This anticipated provider agreement with United Healthcare is a pivotal step forward in our growth trajectory," said Larry Powalisz, CEO of Adia Nutrition Inc. "It enables Adia Med to deliver its advanced, high-demand therapies to a broader population with insurance support, opening the door for accelerated patient acquisition and scalable expansion."
Once approved, Adia Med will join a select network of providers meeting United Healthcare's rigorous standards for clinical excellence, compliance, and patient care. The company has already begun submitting its first patient's insurance claim through UnitedHealthcare-a strong signal of imminent integration.
United Healthcare's partnership not only validates the clinical quality of Adia Med's offerings but also provides a scalable reimbursement pathway for advanced treatments in the fast-growing regenerative medicine sector.
For investor inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA) is a publicly traded company dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events, or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256142
FAQ
When will Adia Nutrition (ADIA) receive United Healthcare provider approval?
What treatments will be covered under the United Healthcare agreement for ADIA?
How will the United Healthcare partnership impact Adia Med's business?
Has ADIA started processing United Healthcare insurance claims?
What does the United Healthcare approval mean for ADIA shareholders?
